How should suspected Guillain‑Barré syndrome be managed?

Management of Suspected Guillain-Barré Syndrome

Initiate intravenous immunoglobulin (IVIg) at 0.4 g/kg daily for 5 days in any patient unable to walk unaided within 2 weeks of weakness onset, as this is the preferred first-line treatment due to ease of administration and equivalent efficacy to plasma exchange. 1

Immediate Recognition and Diagnostic Confirmation

Suspect GBS when you observe:

• Rapidly progressive bilateral limb weakness (legs and/or arms) developing over days to 4 weeks
• Areflexia or hyporeflexia (present in almost all patients at nadir)
• Absence of CNS involvement or alternative causes
• Often preceded by diarrhea or respiratory infection (1-3 weeks prior)

Critical timing: If maximum disability occurs within 24 hours or after 4 weeks, strongly reconsider the diagnosis 1.

Supportive Diagnostic Testing

• CSF examination: Expect albuminocytologic dissociation (elevated protein, normal cell count), though this may be absent early in disease course 2
• Electrophysiology: Helpful but not required to initiate treatment; do not delay therapy waiting for these results
• Anti-GQ1b antibodies: Only if Miller Fisher syndrome suspected (ophthalmoplegia, ataxia, areflexia) 2

ICU Admission Criteria

Admit to ICU immediately if any of the following are present 1:

• Signs of respiratory distress (breathlessness at rest/talking, inability to count to 15 in one breath, accessory muscle use)
• Vital capacity <15-20 ml/kg or <1 liter
• Severe autonomic dysfunction (arrhythmias, marked blood pressure fluctuations)
• Severe bulbar weakness or diminished cough reflex
• Rapid progression of weakness

Use the EGRIS score to calculate probability of requiring mechanical ventilation within 1 week—up to 22% of patients require ventilation in the first week 1.

Treatment Algorithm

First-Line Therapy (Choose One)

Option 1 (Preferred): IVIg

• Dose: 0.4 g/kg/day for 5 consecutive days (total 2 g/kg)
• Timing: Initiate within 2 weeks of weakness onset if unable to walk unaided 1, 2
• Advantages: Easier to administer, more widely available, better tolerated than plasma exchange

Option 2: Plasma Exchange

• Dose: 200-250 ml/kg over 4-5 sessions (total 12-15 L)
• Timing: Within 4 weeks of weakness onset if unable to walk unaided 2
• Consideration: Equally effective as IVIg but requires specialized centers and more monitoring 1

What NOT to Do

Do not use corticosteroids—eight randomized trials showed no benefit, and oral corticosteroids actually worsened outcomes 1.

Do not combine plasma exchange followed by IVIg—no additional benefit over either treatment alone 1.

Do not routinely give a second IVIg course for poor prognosis patients—no evidence supports this approach 2.

Special Populations

Children: Use standard IVIg dosing (0.4 g/kg/day × 5 days). Avoid the 2-day regimen (2 g/kg over 2 days) as treatment-related fluctuations are more frequent (22% vs 0%) 1.

Pregnant women: Both IVIg and plasma exchange are safe; IVIg preferred due to simpler administration 1.

Miller Fisher syndrome: Generally do not treat unless limb weakness, bulbar/facial palsy, or respiratory failure develops—most recover completely without treatment within 6 months 1.

Monitoring Disease Progression

Respiratory Function

• Measure vital capacity regularly in all hospitalized patients
• Monitor for accessory muscle use, tachypnea, tachycardia
• Arterial blood gas and pulse oximetry as needed
• Do not rely solely on clinical signs—respiratory insufficiency can occur without obvious dyspnea 1

Autonomic Function

• Continuous ECG monitoring for arrhythmias
• Frequent blood pressure checks (autonomic instability common)
• Monitor bowel and bladder function
• Stay vigilant during recovery phase—up to two-thirds of GBS deaths occur during recovery from cardiovascular/respiratory complications 1

Neurological Function

• Serial strength assessments (MRC sum scores)
• Swallowing and cough evaluation in patients with bulbar weakness
• Assess for facial palsy (risk of corneal ulceration)

Managing Treatment Failures and Fluctuations

Insufficient Response (40% of patients)

• No improvement within 4 weeks of standard treatment does not necessarily mean treatment failed—progression might have been worse without therapy
• No proven benefit to repeating treatment or switching therapies, though clinicians may consider this 1

Treatment-Related Fluctuations (6-10% of patients)

• Defined as progression within 2 months after initial improvement/stabilization
• Repeat the full course of IVIg or plasma exchange—common practice though evidence is limited 1

Chronic Evolution

• If ≥3 treatment-related fluctuations OR deterioration ≥8 weeks after onset, change diagnosis to acute-onset CIDP (occurs in ~5% of cases) 1

Complication Management

GBS-Specific Complications

• Pain (muscular, radicular, neuropathic): Use gabapentinoids, tricyclic antidepressants, or carbamazepine 2
• Bulbar dysfunction: NPO status, consider NG tube, monitor aspiration risk
• Facial palsy: Eye protection to prevent corneal ulceration
• Psychological symptoms: Screen for anxiety, depression, hallucinations—especially in ICU patients with limited communication 1

Standard ICU Complications

• DVT prophylaxis
• Pressure ulcer prevention
• Hospital-acquired infection prevention (pneumonia, UTI)
• Early mobilization when safe

Critical point: Patients retain full consciousness, vision, and hearing even with complete paralysis—be mindful of bedside conversations and explain all procedures 1.

Prognosis

Use the mEGOS score on admission to predict probability of independent walking at 6 months 1.

Expected outcomes:

• 80% regain independent walking by 6 months 1
• 3-10% mortality (primarily cardiovascular/respiratory complications) 1
• Recovery can continue beyond 3 years after onset 1
• Recurrence is rare (2-5%) 1

Risk factors for poor outcome: Advanced age, severe disease at onset, inability to lift arms at 1 week post-intubation, axonal subtype on electrophysiology 1.

Rehabilitation Planning

Initiate multidisciplinary rehabilitation early involving physiotherapy, occupational therapy, speech therapy, and rehabilitation medicine 1. Exercise programs including range-of-motion exercises, stationary cycling, walking, and strength training improve outcomes 1.